4SCAR-PSMA T cell therapy (Shenzhen Geno-Immune Medical Institute)

N/A

Report date: 2024/11/24 20:00:04

Base Information

Drug Name4SCAR-PSMA T cell therapy (Shenzhen Geno-Immune Medical Institute)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector

Mechanisms of ActionAnti-PSMA

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsLymphoma, B-CellNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaPending

Originator CompaniesShenzhen Geno-Immune Medical Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesShenzhen Geno-Immune Medical Institute

Active IndicationsN/A

Inactive IndicationsLymphoma, B-CellNeoplasms

Other Information

ATC CodeN/A